Why are we not talking to the issue of fostamatinib efficacy?
I have followed RIGL and the science there since Don Payan left his position at UCSF and the Howard Hughes Institute to start that immunology and allergy work. As many academic scientists find out, developing drugs is not as easy as shooting fish in a barrel.
Anyway, after many disappointments, they find a use for their Syk inhibitor. It is a modest platelet boosting agent at best, as only 1 of the two Ph3 studies reached significance in idiopathic thrombocytopenia purpura, ITP. Will it be able to compete with the Amgen peptibody Nplate? How about the small molecule TPO agonist eltrombopag, marketed as Promacta? (Eltrombopag is a bio-organic breakthrough transformative drug in its own right as a small molecule growth factor agonist). I suggest that FDA approval for this RIGL agent in drug resistant ITP is not a slam dunk.
Disclosure: I was a long term holder in RIGL stock over the past couple years, made some $$ on it, but sold most shares after the spike on the first Ph3 Fosta ITP news. No position now.